Equity

Number of Exercisable Options

Merck & Co. Number of Exercisable Options increased by 1.2% to $244.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 1.2%, from $241.00M to $244.00M. Over 5 years (FY 2020 to FY 2025), Number of Exercisable Options shows a downward trend with a -4.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionEquity
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026

How to read this metric

An increase indicates a larger portion of the equity pool is available for immediate conversion, potentially impacting share liquidity.

Detailed definition

The number of share-based payment options that have met all vesting requirements and are currently eligible for exercise...

Peer comparison

Standard metric for assessing immediate dilution risk from employee stock plans.

Metric ID: options_exercisable_number

Historical Data

5 periods
 Q4 '21Q4 '22Q4 '23Q4 '24Q4 '25
Value$198.00M$399.00M$379.00M$241.00M$244.00M
QoQ Change+101.5%-5.0%-36.4%+1.2%
YoY Change+101.5%-5.0%-36.4%+1.2%
Range$198.00M$399.00M
CAGR+23.2%
Avg YoY Growth+15.3%
Median YoY Growth-1.9%

Number of Exercisable Options at Other Companies

Frequently Asked Questions

What is Merck & Co.'s number of exercisable options?
Merck & Co. (MRK) reported number of exercisable options of $244.00M in Q4 2025.
How has Merck & Co.'s number of exercisable options changed year-over-year?
Merck & Co.'s number of exercisable options increased by 1.2% year-over-year, from $241.00M to $244.00M.
What is the long-term trend for Merck & Co.'s number of exercisable options?
Over 5 years (2020 to 2025), Merck & Co.'s number of exercisable options has grown at a -4.6% compound annual growth rate (CAGR), from $309.00M to $244.00M.
What does number of exercisable options mean?
The number of stock options that employees are currently allowed to convert into shares.